As of Feb 23
| -0.02 / -0.80%|
The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +41.13% increase from the last price of 2.48.
The current consensus among 2 polled investment analysts is to Buy stock in PDL BioPharma Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.